Evidence map›Paper›PMID 28582029›Full record

ReviewInterventional cardiology clinics2016

Endovascular Drug Delivery and Drug Elution Systems: First Principles.

Abraham Rami Tzafriri, Elazer Reuven Edelman

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Interventional cardiology clinics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Endovascular Drug Delivery.Life (Basel, Switzerland) · 2024
    Review
  2. Controlled and Targeted Drug Delivery Using Smart Nanovectors.International journal of drug discovery and pharmacology · 2023
    Article
  3. Vascular Lesion-Specific Drug Delivery Systems: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2021
    Review
  4. Evolution of drug-eluting biomedical implants for sustained drug delivery.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2021
    Review
  5. Article
  6. Defining drug and target protein distributions after stent-based drug release: Durable versus deployable coatings.Journal of controlled release : official journal of the Controlled Release Society · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Abraham Rami TzafririDepartment of Applied Sciences, CBSET, Lexington, MA, USA; IMES, MIT, 77 Massachusetts Avenue, Building E25-438, Cambridge, MA 02139, USA. Electronic address: rtzafriri@cbset.org.
Elazer Reuven EdelmanIMES, MIT, 77 Massachusetts Avenue, Building E25-438, Cambridge, MA 02139, USA; Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.

Funding

Vascular Drug Delivery - Supplement for EquipmentR01GM049039 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI EDELMAN, ELAZER R · 1994 to 2019
$8.9M
NIGMS NIH HHS R01 GM049039
6 · The paper itself

Abstract

Endovascular drug delivery continues to revolutionize the treatment of atherosclerosis in coronary and peripheral vasculature. The key has been to identify biologic agents that can counter the hyperplastic tissue responses to device expansion/implantation and to develop effective local delivery strategies that can maintain efficacious drug levels across the artery wall over the course of device effects. This article reviews the evolution of endovascular drug delivery technology, explains the mechanisms they use for drug release, and provides a quantitative mechanistic framework for relating drug release mode to arterial drug distribution and effect.

Indexed as

Drug-Eluting StentsCoronary RestenosisDrug Delivery SystemsDrug LiberationHumansStentsControlled releaseDiffusionDissolutionDistributionDrug-eluting stentsDrug-filled stentsPolymer-free stentsRetention

Identifiers

PMID28582029
PMCPMC6661070

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.